Publications by authors named "Tymara Berry"

Claim this Profile
N
No Effect of Immunogenicity on Pharmacokinetics, Efficacy, and Safety of the Oligonucleotide Telomerase Inhibitor Imetelstat in Lower-Risk Myelodysplastic Syndromes.
Ashley L Lennox, Fei Huang, Mario González-Sales, Ying Wan, Libo Sun, Tymara Berry

Clin Transl Sci· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical outcomes and safety in patients with lower-risk myelodysplastic syndromes treated with imetelstat: Substudy of the phase 3 IMerge trial.
Rami S Komrokji, Valeria Santini, Uwe Platzbecker, Koen Van Eygen, María Díez-Campelo, Tymara Berry

Br J Haematol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low Proarrhythmic Risk of Imetelstat, a Novel Oligonucleotide Telomerase Inhibitor: A Translational Analysis.
Ashley L Lennox, Libo Sun, Fei Huang, Melissa Kelly Behrs, Robert Kleiman, Tymara Berry

Clin Transl Sci· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Imetelstat, a novel, first-in-class telomerase inhibitor: Mechanism of action, clinical, and translational science.
Ashley L Lennox, Fei Huang, Melissa Kelly Behrs, Mario González-Sales, Neha Bhise, Tymara Berry

Clin Transl Sci· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics of imetelstat, a first-in-class oligonucleotide telomerase inhibitor.
Mario González-Sales, Ashley L Lennox, Fei Huang, Chandra Pamulapati, Ying Wan, Tymara Berry

CPT Pharmacometrics Syst Pharmacol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial.
Uwe Platzbecker, Valeria Santini, Pierre Fenaux, Mikkael A Sekeres, Michael R Savona, Tymara Berry

Lancet· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Imetelstat in intermediate-2 or high-risk myelofibrosis refractory to JAK inhibitor: IMpactMF phase III study design.
John Mascarenhas, Claire N Harrison, Jean-Jacques Kiladjian, Rami S Komrokji, Steffen Koschmieder, Tymara Berry

Future Oncol· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure.
Claire N Harrison, Nicolaas Schaap, Alessandro M Vannucchi, Jean-Jacques Kiladjian, Eric Jourdan, Tymara Berry

Am J Hematol· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
-
-Paclitaxel-Based Therapy in Underserved Patient Populations: The ABOUND.PS2 Study in Patients With NSCLC and a Performance Status of 2.
Ajeet Gajra, Nagla Abdel Karim, Deborah A Mulford, Liza Cosca Villaruz, Marc Ryan Matrana, Tymara Berry

Front Oncol· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
-
-Paclitaxel-Based Therapy in Underserved Patient Populations: The ABOUND.70+ Study in Elderly Patients With Advanced NSCLC.
Corey J Langer, Edward S Kim, Eric C Anderson, Robert M Jotte, Manuel Modiano, Tymara Berry

Front Oncol· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
'
'No child need have rickets' revisited.
Tymara Berry, Robert Rapaport

J Pediatr Endocrinol Metab· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis